Nat CommunJClub
Engineering the paclitaxel biosynthetic pathway in Physcomitrium patens for de novo and stable biosynthesis.
Nature Communications · · Journal Article · Open access
Zhao, Lu + more
Abstract ↗AI summary
The abstract is read at the publisher; the summary is JClub's.
Engineered Physcomitrium patens strains can stably produce paclitaxel after multiple subcultures, demonstrating potential as a plant chassis for biosynthesis.
- Why it matters: Producing paclitaxel through biosynthesis addresses the low efficiency and high cost of extraction from yew trees and semi-synthesis, filling a critical gap in sustainable drug production.
- What they did: The study combined transient expression, cytoplasmic localization, multi-gene co-expression via 2 A peptides, and modular iterative transformation to engineer paclitaxel biosynthesis in P. patens, creating stable producing lines.
- The result: The engineered lines maintained paclitaxel production after repeated subculturing, suggesting P. patens can serve as a reliable platform for de novo biosynthesis of this anticancer drug.
The findingWhy it mattersWhat they didThe result
- Open access